Drug Profile
Peanut allergy immunotherapy - DBV Technologies
Alternative Names: Current Viaskin peanut patch; cVP; DBV 712; EPIT®; Modified Viaskin peanut patch; mVP; Viaskin Peanut; ViaskinTM PeanutLatest Information Update: 14 Nov 2023
Price :
$50
*
At a glance
- Originator DBV Technologies
- Class Allergens; Antiallergics; Food allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Peanut hypersensitivity
Most Recent Events
- 09 Nov 2023 Interim efficacy and safety data from the phase III EPOPEX trial in Peanut hypersensitivity released by DBV Technologies
- 31 Oct 2023 DBV Technologies plans the phase III COMFORT Children trial for Peanut hypersensitivity (In children) (Cutaneous, Patch)
- 31 Oct 2023 DBV Technologies plans the phase III COMFORT Toddlers trial for Peanut hypersensitivity (In infants, In children) in Q1 2023 (Cutaneous, Patch)